The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ALVO | -33.63% | N/A | N/A | -13% |
| S&P | +14.5% | +93.32% | +14.09% | +89% |
Alvotech operates as a global biopharmaceutical company, which engages in developing and manufacturing biosimilar medicines. It operates through the following geographical segments: North America, Europe, Asia, and Other. The company was founded by Róbert Wessman on August 23, 2021 and is headquartered in Luxembourg.
The biosimilar drug company's shares rebounded a day after it announced that the FDA had dealt it setback.
The Icelandic biotech company has a deal to expand the reach of its Humira biosimilar in Eastern Europe.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $173.24M | -12.8% |
| Gross Profit | $99.41M | -35.2% |
| Gross Margin | 57.39% | -19.9% |
| Market Cap | $2.75B | -19.0% |
| Market Cap / Employee | $2.67M | 0.0% |
| Employees | 1K | 0.6% |
| Net Income | $32.04M | -50.9% |
| EBITDA | $26.85M | -73.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $151.45M | 1283.9% |
| Accounts Receivable | $154.77M | 16.1% |
| Inventory | 155.5 | 61.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.21B | 576.0% |
| Short Term Debt | $59.62M | -94.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 5.15% | 67.6% |
| Return On Invested Capital | -170.25% | 34.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $42.12M | 174.2% |
| Operating Free Cash Flow | $55.74M | 210.2% |
| Metric | Q1 2025 | Q2 2025 | YoY Change | ||
|---|---|---|---|---|---|
| Price to Earnings | 28.68 | 43.45 | - | ||
| Price to Book | -5.49 | -11.60 | -7.07 | -9.11 | 84.89% |
| Price to Sales | 9.76 | 8.58 | 4.98 | 4.91 | -59.16% |
| Price to Tangible Book Value | -5.22 | -10.60 | -6.56 | -8.22 | 74.77% |
| Enterprise Value to EBITDA | 221.20 | 263.30 | 218.45 | 144.09 | 213.08% |
| Total Debt | $1.18B | $1.19B | $1.23B | $1.27B | 6.70% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
